Replies to post #225825 on Biotech Values

[jbog]

Has Enanta ever stated the reason for a follow on FXR candidate?

tia

[DewDiligence]

ENTA latest slide set (7/11/19):

https://s22.q4cdn.com/306858242/files/doc_presentations/2019/07/17/July-11-2019-Corporate-Presentation.pdf

[DewDiligence]

ENTA FY4Q19 results:

https://www.enanta.com/investors/news-releases/press-release/2019/Enanta-Pharmaceuticals-Reports-Financial-Results-for-its-Fiscal-Fourth-Quarter-and-Year-Ended-September-30-2019/default.aspx

FY4Q19 royalty revenue=$51.3M, up from $44.4M in FY3Q19 (Apr-Jun 2019).

ENTA’s royalty rate from ABBV resets to the lowest tier at the start of each calendar year; the royalty tiers applicable to the 50% Glecaprevir component of Mavyret are shown in #msg-142808661.

9/30/19 cash=$400M.

FY4Q19 GAAP EPS=$0.44.

FY2020 R&D guidance is $155-175M.